SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Clin. transl. oncol. (Print)
; 25(9): 2634-2646, sept. 2023. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-224130
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 510%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias Encefálicas
/
Glioma
Limite:
Humanos
País/Região como assunto:
Europa
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2023
Tipo de documento:
Artigo
Instituição/País de afiliação:
Catalan Institute of Oncology/Spain
/
Complejo Asistencial Universitario de Salamanca/Spain
/
Complejo Hospitalario Universitario de Orense/Spain
/
Hospital Univeristari i Politècnic La Fe/Spain
/
Hospital Universitario Doctor Josep Trueta/Spain
/
Hospital Universitario Marqués de Valdecilla/Spain
/
Hospital de Sant Pau i La Santa Creu/Spain
/
Hospital del Mar/Spain
/
IDIBAPS/Spain
/
IdISCC/Spain